Cargando...
Relapse rates in patients with multiple sclerosis treated with fingolimod: subgroup analyses of pooled data from three phase 3 trials
BACKGROUND: Fingolimod is a once-daily, orally administered therapy for relapsing forms of MS. It has been shown to reduce relapse rates significantly in all phase II and phase III clinical trials when compared with placebo and intramuscular interferon β-1a (IFNβ-1a IM). METHODS: This study compared...
Guardado en:
| Publicado en: | Mult Scler Relat Disord |
|---|---|
| Autores principales: | , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4985567/ https://ncbi.nlm.nih.gov/pubmed/27456887 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.msard.2016.05.015 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|